Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
Status:
Completed
Trial end date:
2021-02-19
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled
Esketamine in participants with treatment-resistant bipolar depression (TRBD). The study is
to determine the efficacy and dose response of three Esketamine doses, compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Celon Pharma SA
Collaborator:
National Center for Research and Development, Poland